Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Arch. cardiol. Méx ; 76(3): 257-262, jul.-sept. 2006.
Article in Spanish | LILACS | ID: lil-568735

ABSTRACT

BACKGROUND: Long QT syndromes (LQTS) are inherited cardiac disorders caused by mutations in the genes that encode sodium or potassium transmembrane ion channel proteins. More than 200 mutations, in at least six genes, have been found in these patients. The Jervell and Lange-Nielsen (JLN) syndrome is the recessive form of the disease and is associated with deafness. Few families with JLN syndrome and genetic studies are reported in the literature. METHODS: The KCNQ1 (KvLQT1) gene in a Mexican family with Jervell-Lange-Nielsen long QT syndrome was analyzed using an automated sequence method. RESULTS: A missense mutation was found in the three affected individuals. This mutation is associated with complete loss of channel function. Correlation with the phenotype showed a prolonged QTc interval and deafness in the two siblings homozygous to the mutation. The mother, who was heterozygous for the mutation, also had prolonged QTc interval without deafness. The father and younger brother had normal QTc intervals. The mutation was not found in 50 healthy controls studied. CONCLUSIONS: We describe for the first time a mutation in the KCNQ1 gene in a Mexican family with JLN long QT syndrome. This mutation produces an amino acid change (Gly-Arg) at protein level at the 168 residue. This mutation has been previously reported in Caucasian families with LQTS.


Subject(s)
Adolescent , Child , Child, Preschool , Female , Humans , Male , Jervell-Lange Nielsen Syndrome , KCNQ1 Potassium Channel , Mutation, Missense , Mexico , Pedigree
2.
Arch. Inst. Cardiol. Méx ; 60(5): 479-84, sept.-oct. 1990. tab
Article in Spanish | LILACS | ID: lil-99104

ABSTRACT

Se presentan los criterios que a nuestro juicio con las claves para la selección de un antiarrítmico dentro de los que se consideran el substrato de la arritmia, el factor disparador, los factores moduladores como puntos centrales. Al mismo tiempo se mencionan en forma general los sitios donde actúan los medicamentos antiarrítmicos, sus efectos generales, las posibilidades de falla y finalmente las bases para la combinación de estos fármacos


Subject(s)
Humans , Anti-Arrhythmia Agents/pharmacokinetics , Anti-Arrhythmia Agents/metabolism , Anti-Arrhythmia Agents/therapeutic use , Arrhythmias, Cardiac/therapy , Drug Combinations
SELECTION OF CITATIONS
SEARCH DETAIL